SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer is a phase 2/3, randomised interventional study registered as NCT07662811 by Shanghai Chest Hospital, with a registry enrolment figure of 396 participants, started 2026-06-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: SYHX2011; Carboplatin; Enlonstobart; Nab-Paclitaxel; Carboplatin; Tislelizumab. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR) for phase II; Progression Free Survival (PFS) for phase III. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced or metastatic squamous non-small cell lung cancer (Stage IIIB, IIIC, or IV according to the IASLC 9th Edition TNM Staging System), ineligible for radical surgery and/or radical radiotherapy". No results are recorded here; the registry entry is the source.